Yoshiike T, Aikawa Y, Sindhvananda J, Ogawa H
Department of Dermatology, Juntendo University School of Medicine, Tokyo, Japan.
J Dermatol Sci. 1993 Feb;5(1):50-3. doi: 10.1016/0923-1811(93)90105-x.
Psoralen photochemotherapy with UVA (PUVA) has been reported to be successfully substitutional for, or an adjunct to, conventional treatments in patients with atopic dermatitis (AD). Against the considerable advantages of utilizing PUVA for AD patients, however, it must also be balanced against the possible hazards for individual patients. We attempted herein to formulate a guideline for the selection of AD patients assigned to PUVA. According to this guideline, 114 patients were selected for PUVA treatment. Forty-five percent of the patients did not respond adequately to other conventional forms of treatment. Side effects from former treatments, particularly steroids, appeared in 39% of the patients. Subsequent to the treatments, the skin lesions significantly decreased in 81% of the inpatients and 67% of the outpatients, while some patient's lesions disappeared, despite that other forms of treatment had been unsuccessful in many cases.
据报道，补骨脂素光化学疗法联合长波紫外线（PUVA）可成功替代或辅助治疗特应性皮炎（AD）患者的传统治疗方法。然而，在认识到PUVA对AD患者具有显著优势的同时，也必须权衡其对个体患者可能带来的风险。我们在此尝试制定一份针对接受PUVA治疗的AD患者的选择指南。根据该指南，114例患者被选作PUVA治疗对象。45%的患者对其他传统治疗方式反应欠佳。39%的患者曾出现过先前治疗尤其是类固醇治疗的副作用。治疗后，81%的住院患者和67%的门诊患者皮肤病变显著减轻，尽管在许多情况下其他治疗方式均未成功，但仍有部分患者的病变消失。
